²é¿´: 3195  |  »Ø¸´: 14

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


[½»Á÷] ÌåÍⰲȫÐÔÆÀ¼Û¡ª¡ªÒ»¸öÐÂÐ˵ÄÍâ°üÊг¡£¿ ÒÑÓÐ11È˲ÎÓë

Ò©Îï¶¾ÐÔ·ÖΪon-target¶¾ÐÔºÍoff-target¶¾ÐÔ£¬µ¥¿Ë¡¿¹ÌåµÄÑ¡ÔñÐԸߣ¬Ö÷ÒªÊÇon-target¶¾ÐÔ£¬ÕâÖÖ¶¾ÐÔ¿ÉÄÜÊǰÐ×éÖ¯exaggerated pharmacology£¬Ò²¿ÉÄÜÊǶԷǰÐ×éÖ¯µÄon-target pharmacologyµ¼Ö£¬¶øoff-target¶¾ÐÔÖ÷Òª±íÏÖÔÚС·Ö×Ó¼°Æä´úл²úÎïÖС£75%µÄÒ©Î︱×÷ÓÃÊÇdose-dependent£¬²¢ÇÒ¿ÉÒÔͨ¹ýpharmacology profilesÔ¤²â¡£

ÌåÍâSPP£¨in vitro safety pharmacology profiling£©ÊÇŵ»ª¿ÆÑ§¼ÒÔÚ2005ÄêÌá³öµÄ¸ÅÄËüµÄ¶¨ÒåÊÇÔÚÒ©ÎïÑз¢ÔçÆÚ£¨Ïȵ¼»¯ºÏÎïÑ¡ÔñºÍ½á¹¹ÓÅ»¯¹ý³ÌÖУ©£¬Í¨¹ý²âÊÔһϵÁÐoff-target£¬³õ²½Ô¤²âÒ©Î︱×÷Ó㬲¢Ö¸µ¼½á¹¹ÓÅ»¯£¬Ñ¡³ö°²È«ÐÔ×îºÃµÄ·Ö×Ó½øÈ붯ÎïʵÑé¡£ÌåÍâSPPµÄÖÕ¼«Ä¿µÄÊÇÌá¸ßÒ©ÎïÔÚ¶¯ÎïʵÑéºÍÁÙ´²µÄ³É¹¦ÂÊ¡£

ÌåÍâSPPµÄÓŵ㣺
1.³É±¾µÍ¡¢Ëٶȿ죻
2.ÔÚÏȵ¼»¯ºÏÎïÓÅ»¯µÄʱºò¾Í·¢ÏÖ¶¾ÐÔ£¬¿ÉÒÔÖ¸µ¼½á¹¹ÓÅ»¯£¬¶ø´«Í³µÄ°²È«ÐÔÆÀ¼ÛÒÀÀµ¶¯ÎïʵÑéºÍÁÙ´²Ñо¿£¬·Ö×ÓºóÆÚÑз¢Ê§°Ü£¬ºÜÄѻعýÍ·À´½øÐнṹÓÅ»¯£»
3.ÓÉÓÚ¶¯ÎïÓëÈËÌåµÄ²îÒ죬ijЩ¸±×÷ÓÃͨ¹ý¶¯ÎïʵÑéÊÇ·¢ÏÖ²»Á˵쬲»Èç5-HT2BÒýÆðµÄÐİêĤËðÉË£¬¶øÌåÍâSPPÓõÄÊÇÈËÌåµ°°×£¬¿ÉÒÔÔ¤²âÕâ·½ÃæµÄ¸±×÷Óá£

ÌåÍâSPPµÄǰÌáÓÐÁ½¸ö£º
µÚÒ»£¬È·Ö¤off-targetÓ븱×÷ÓõĹØÏµ£¬¶¾ÀíѧµÄ¶«Î÷£¬ËäÈ»ºÜÄÑ£¬ºÃÔÚÒ»µ©È·Ö¤£¬´ó¼Ò¶¼¿ÉÒÔÓá£
µÚ¶þ£¬ÈçºÎÑ¡Ôñoff-target¼¯£¬ÕâÈ¡¾öÓÚ¸÷ÆóÒµ×Ô¼ºµÄ³É±¾¡ª¡ªÐ§Òæ·ÖÎö¡£²âÊÔµÄoff-targetÔ½¶à£¬ÌåÍâSPPµÄ½á¹ûԽ׼ȷ£¬µ«»¨µÄÇ®×ÔȻԽ¶à¡£Ä³¸öoff-targetÊÇ·ñÐèÒª²âÊÔ£¬È¡¾öÓÚËüµÄhit rateºÍimpact£¬Åµ»ª²âÊÔÁË1832¸ö»¯ºÏÎÆäÖÐ980¸ö»¯ºÏÎï¶ÔhERGµÄIC50СÓÚ30¦ÌM£¬Õâ¾ÍÊǸßhit rateÁË£¬¶øhERGÒÖÖÆÒýÆðÐÄÂÉʧ³£ÉõÖÁËÀÍö£¬Õâ¾ÍÊǸßimpact£¬ËùÒÔhERG±ØÐëÑ¡Èëoff-target¼¯¡£¶øÄ³Ð©off-target±ÈÈçÍʺÚËØÊÜÌåMT3£¬¾¡¹Ühit rateÒ²´óÓÚ30%£¬ÓÉÓÚûÓÐÑÏÖØ¸±×÷Óã¬Òò´Ë¿ÉÒÔ²»¿¼ÂÇ¡£

ÌåÍâSPP¿ÉÒԷֽ׶νøÐУ¬Ç°ÆÚ»¯ºÏÎïÊýÁ¿¶à£¬¿ÉÒÔ²âÊÔÉÙÁ¿µÄoff-target£¬¶ø×¼±¸×ö¶¯ÎïʵÑ飬ֻʣÏÂÒ»¸öºòÑ¡·Ö×Ó£¬¾Í¿ÉÒÔÀ©´óoff-target¼¯¡£²âÊÔoff-targetÒ²ÊÇÓн²¾¿µÄ£¬¿ÉÒÔÖ»²âÒ»¸öŨ¶È£¨Ò»°ã10¦ÌM£©£¬¸ü׼ȷһµã¿ÉÒÔ²â¶à¸öŨ¶È£¬¼ÆËã¸÷×ÔµÄIC50Öµ¡£Åµ»ª·Ö½×¶Î½øÐÐÌåÍâSPP£º
primary panel (23 targets): lead chemical seriesµÄÑ¡Ôñ¡¢lead optimization¹ý³ÌÖеÄrapid check£»
second panel (70 targets): ÔÚ½øÈëpreclinical֮ǰ£¬½øÒ»²½characterize the candidate£»
third panel (85 additional targets): fullÑ¡ÔñÐÔÆÀ¼Û¡£

²âÊÔoff-target»îÐԺ󣬾ͿÉÒÔ×÷promiscuity·ÖÎö£¬IC<10¦ÌMµÄËã×÷ÃüÖУ¬ÃüÖеÄoff-target³ýÒÔ×ܵÄoff-targetÊý¾ÍµÃ³öpromiscuityÖµ£¬promiscuityÖµÔ½´ó£¬·Ö×Ó°²È«ÐÔÔ½µÍ£¬promiscuityÖµ´óÓÚ20%¾ÍÊǸßΣÁË£¬ÊÇ·ñ½øÈ붯ÎïʵÑé¾ÍÐèÒªÉ÷ÖØ¿¼ÂÇ¡£°´Åµ»ªµÄͳ¼ÆÊý¾Ý£¬ÁÙ´²Ê§°ÜºÍÉÏÊк󳷻صÄÒ©ÎïÖУ¬promiscuityÖµÔÚ20%ÒÔÉϵÄÕ¼1/5ÒÔÉÏ£¬¶ø³É¹¦µÄÒ©ÎïÖУ¬promiscuityÖµÔÚ20%ÒÔÉϵÄÖ»Õ¼1/20¡£

promiscuityÖµ²»ÊÇÒ»¸ö¾ø¶ÔµÄ¸ÅÄÒòΪÿ¸öoff-targetµÄÓ°ÏìÁ¦²»Í¬£¬Èç¹ûÒ»¸ö·Ö×Ó¶ÔhERGÓÐÒÖÖÆ»îÐÔ£¬¼´±ãûÓÐÃüÖÐÆäËûµÄoff-target£¬Ò²ÊDz»ÄܽøÈëÁÙ´²µÄ¡£Í¬Ê±²»Í¬Ò©Îï¶Ô¸±×÷ÓõÄÒªÇó²»Ò»Ñù£¬ÍíÆÚ°©Ö¢Ò©Îï¿ÉÒÔ¶Ô¸±×÷ÓÃ·Å¿í£¬¶øÄ³Ð©ÐèÒª³¤ÆÚÓÃÒ©µÄ·ÇÖÂËÀÐÔ¼²²¡ÔòÒªÑϸñ¿ØÖƸ±×÷Ó㬶ÔÌåÍâSPPÆÀ¼Û½á¹ûµÄ·ÖÎö¿¿Ñо¿Õß×Ô¼º¡£

ÓÉÓÚÒÖÖÆhERG£¬±»ÕٻصÄÒ©ÎïÓУºTerodiline (IC50=450nM); Terfenadine (IC50=204nM); Sertindole (IC50=3nM); Astemizole (IC50=0.9nM); Grepafloxacin (IC50=50¦ÌM); Levomethadyl acetate (IC50=3¦ÌM); Cisapride (IC50=15nM); Droperidol (IC50=32nM)¡£FDAÒªÇóÁÙ´²Ñо¿Ç°²â¶¨hERG»îÐÔ£¬±ÜÃâÐÄÂÉʧ³£¸±·´Ó¦¡£

²Î¿¼ÎÄÏ×£º
Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012, 11, 909-922.
Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005, 10, 1421-1433.
Hamon J, Whitebread S, Techer-Etienne V, Le Coq H, Azzaoui K, Urban L. In vitro safety pharmacology profiling: what else beyond hERG? Future Med Chem. 2009, 1, 645-665.
Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012, 11, 751-761.

[ Last edited by ³ÕÃÎäìÏæ on 2012-12-11 at 10:23 ]
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
»ØÌûÖ§³Ö ( ÏÔʾ֧³Ö¶È×î¸ßµÄǰ 50 Ãû )

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


¡ï
marktiger: ½ð±Ò+1, лл·ÖÏí 2012-12-13 08:35:38
ÒýÓûØÌû:
5Â¥: Originally posted by yzshua1987 at 2012-12-11 19:33:17
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿

Ò©Îï·Ö×ÓÒ»°ã×÷ÓÃÓÚij¸ötarget¶ø²úÉú×÷Óã¬Õâ¸ötarget¿ÉÄÜÊÇÊÜÌ塢ø¡¢Àë×ÓͨµÀ£¬on-target¶¾ÐÔÊÇ×÷ÓÃÁ˶ԵÄtarget£¬µ«ÈÔÈ»²úÉúÁ˶¾ÐÔ£¬±ÈÈçij¸ötargetÔÚÈ«Éí¶¼Óзֲ¼£¬¶øÒªÖÎÁƵIJ¡È´ÊÇij¸öÆ÷¹Ù¾Ö²¿£¬Õâʱ¾Í»áÓÐon-target¶¾ÐÔ£¬µ±È»Ò²ÓпÉÄÜÊǹý¶È×÷ÓÃÒýÆðÁË£¬±ÈÈ罵ѪÌÇÒ©£¬µ±ÑªÌǻعéÕý³£ºó£¬Ò©ÎïÈÔÈ»·¢»Ó×÷Ó㬾ͻá²úÉúµÍѪÌǸ±×÷Óá£off-target¶¾ÐÔÊÇÖ¸×÷Óõ½ÁËÖÎÁÆÒÔÍâµÄtarget¶ø²úÉú¶¾ÐÔ£¬±ÈÈçij¸ö¿¹¾«Éñ²¡Ò©ÓÐÐÄÂÉʧ³£µÄ¸±×÷Óã¬ÄÇôÕâ¸öÒ©¿ÉÄܼÈ×÷Óõ½¿¹¾«Éñ²¡µÄtarget£¬Í¬Ê±»¹×÷Óõ½Á˼ØÀë×ÓͨµÀhERG£¬ÒýÆðÐÄÂÉʧ³£¡£
7Â¥2012-12-12 09:09:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÕÅÑàÃÄ

½ð³æ (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÎÒÏÖÔÚ¾ÍÊÇרÃÅ×öSPPµÄÁË£¬ºÙºÙ£¬¿´µ½ÕâÆªÎÄÕÂͦ¿ªÐĵģ¬ËµÃ÷ÎҵĻîºÜÖØÒªÑ½
ŬÁ¦¹¤×÷£¬¿ìÀÖÉú»î
11Â¥2012-12-13 13:35:28
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
ÆÕͨ»ØÌû
2Â¥2012-12-11 11:33:19
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

cpujacs

ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷


ºÃ¶«Î÷
3Â¥2012-12-11 13:44:40
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

niebiao2008

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

study

ȷʵÌåÍâÆÀ¼ÛÒѾ­Ô½À´Ô½Êܵ½ÖØÊÓÁË£¬¶øÇÒǰÆÚ·¢ÏÖÎÊÌâ¿ÉÒÔ´ó´ó½µµÍºóÐø¿ª·¢µÄ·çÏÕ
²»¶Ïѧϰ,²»¶Ï½ø²½!
4Â¥2012-12-11 15:46:04
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yzshua1987

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿
ÎҺܱ¿¡£¡£¡£¡£¡£¡£¡£¡£µ«ÊÇÎÒÔ¸Òâ±£³ÖÎÒµÄÎïÖÖÌØÒìÐÔ£¡
5Â¥2012-12-11 19:33:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

marktiger

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÒýÓûØÌû:
5Â¥: Originally posted by yzshua1987 at 2012-12-11 19:33:17
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿

×÷ÓÃÔڰеãÆ÷¹ÙµÄ¶¾ÐԺͰеãÆ÷¹ÙÖ®ÍâµÄ¶¾ÐÔ£¿
marktigerchen
6Â¥2012-12-12 08:45:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

nichn

Òø³æ (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
¾ßÌåÈçºÎ²âÊÔÄØ£¿
8Â¥2012-12-12 13:47:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


ÒýÓûØÌû:
8Â¥: Originally posted by nichn at 2012-12-12 13:47:58
¾ßÌåÈçºÎ²âÊÔÄØ£¿

ø¡¢ÊÜÌå¡¢Àë×ÓͨµÀµÄ²âÊÔ·½·¨¸÷²»Ïàͬ£¬¾ßÌåÔõô²â£¬×öÒ©ÀíµÄÈËÓ¦¸Ã¶¼ºÜÇå³þ£¬Ö»²»¹ýƽʱֻ²âÒ»¸ötarget£¬×öÌåÍâSPPÐèÒª×öÉϰٸötarget£¬µ¥¸öÆóÒµ´ó¸ÅÒ²¾Íŵ»ªÕâÖÖ³¬´óºÅµÄ²Å×öµÃÆð£¬¹úÄÚÈç¹ûÓй«Ë¾×öÍâ°ü£¬Î´±ØÅª²»ÆðÀ´£¬¼¯³É»¯µÄЧÂʱȵ¥¸É¸ßµÃ¶à¡£¹úÄÚ¿ÉÒÔÏÈ´ÓhERGµ¥¸ö°Ðµã¿ªÊ¼×ö£¬±Ï¾¹Õâ¸ö¸±×÷ÓðеãÊÇFDAÒªÇó±ØÐë×öµÄ£¬È»ºó·¢Õ¹ÆðС¹æÄ£panel¡¢ÖйæÄ£panel¡¢´ó¹æÄ£panel£¬Îª¸÷´óÖÆÒ©ÆóÒµÁÙ´²Ç°¸÷½×¶ÎÌṩÌåÍⰲȫÐÔÆÀ¼Û²ÎÊý¡£
9Â¥2012-12-12 14:07:32
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

arrow6911

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

¸±½ÌÊÚ

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
marktiger: ÇëÔĶÁÍêºóÔÙÌáÎÊ£¬¾¡Á¿²»ÒªÖظ´ÌáÎÊ¡£ 2012-12-13 08:36:15
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿
iamcoming!
10Â¥2012-12-12 15:11:25
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ³ÕÃÎäìÏæ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0854µç×ÓÐÅÏ¢Çóµ÷¼Á 324 +3 Promise-jyl 2026-03-23 3/150 2026-03-23 13:43 by wangkm
[¿¼ÑÐ] ±±¿Æ281ѧ˶²ÄÁÏÇóµ÷¼Á +8 tcxiaoxx 2026-03-20 9/450 2026-03-23 12:16 by tcxiaoxx
[¿¼ÑÐ] 284Çóµ÷¼Á +6 Zhao anqi 2026-03-22 6/300 2026-03-23 09:23 by king123£¡
[¿¼ÑÐ] 289²ÄÁÏÓ뻯¹¤£¨085600£©BÇøÇóµ÷¼Á +3 ÕâôÃû×ÖÕ¦Ñù 2026-03-22 4/200 2026-03-22 17:56 by ÔÆÃñ´óÀîÀÏʦ
[¿¼ÑÐ] ÉúÎïѧ071000 329·ÖÇóµ÷¼Á +5 ÎÒ°®ÉúÎïÉúÎﰮΠ2026-03-17 5/250 2026-03-22 16:42 by tcx007
[¿¼ÑÐ] 305·ÖÇóµ÷¼Á£¨Ê³Æ·¹¤³Ì£© +4 Sxy112 2026-03-21 6/300 2026-03-22 15:26 by ÎÞи¿É»÷111
[¿¼ÑÐ] Çóµ÷¼Á +7 Auroracx 2026-03-22 7/350 2026-03-22 12:38 by ËØÑÕÇã³Ç1988
[¿¼ÑÐ] 354Çóµ÷¼Á +7 Tyoumou 2026-03-18 10/500 2026-03-22 11:11 by ÈËÀ´Ê¢
[¿¼ÑÐ] 278Çóµ÷¼Á +9 ÑÌ»ðÏÈÓÚ´º 2026-03-17 9/450 2026-03-21 17:47 by ѧԱ8dgXkO
[»ù½ðÉêÇë] ѧУÒѾ­Ìá½»µ½NSFC£¬»¹ÄÜÐÞ¸ÄÂ𣿠40+4 babangida 2026-03-19 9/450 2026-03-21 16:12 by babangida
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤£¨0856£©304Çó BÇø µ÷¼Á +3 Çñgl 2026-03-21 3/150 2026-03-21 13:47 by lature00
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÄÏʦ´ó 070300£¨»¯Ñ§£©304·ÖÇóµ÷¼Á +3 0703ÎäÜ·»ÛÑ©304 2026-03-18 3/150 2026-03-21 00:48 by JourneyLucky
[¿¼ÑÐ] 288Çóµ÷¼Á +16 ÓÚº£º£º£º£ 2026-03-19 16/800 2026-03-20 22:28 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏѧ˶297ÒѹýËÄÁù¼¶Çóµ÷¼ÁÍÆ¼ö +11 adaie 2026-03-19 11/550 2026-03-20 21:30 by laoshidan
[¿¼ÑÐ] Çóµ÷¼Á +3 @taotao 2026-03-20 3/150 2026-03-20 19:35 by JourneyLucky
[¿¼ÑÐ] Çóµ÷¼Á +3 eation27 2026-03-20 3/150 2026-03-20 19:32 by JourneyLucky
[¿¼ÑÐ] 298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á +9 ÊÖ»úÓû§ 2026-03-17 9/450 2026-03-20 14:24 by ÎÞи¿É»÷111
[¿¼ÑÐ] 085410È˹¤ÖÇÄÜר˶317Çóµ÷¼Á£¨0854¶¼¿ÉÒÔ£© +4 xbxudjdn 2026-03-18 4/200 2026-03-20 09:07 by ²»168
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +3 ÄÝÄÝninicgb 2026-03-17 3/150 2026-03-18 10:29 by macy2011
[¿¼ÑÐ] Ò»Ö¾Ô¸ËÕÖÝ´óѧ²ÄÁϹ¤³Ì£¨085601£©×¨Ë¶ÓпÆÑо­ÀúÈýÏî¹ú½±Á½¸öʵÓÃÐÍרÀûÒ»ÏîÊ¡¼¶Á¢Ïî +6 ´ó»ðɽС»ðɽ 2026-03-16 8/400 2026-03-17 15:05 by ÎÞи¿É»÷111
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û